These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2297869)

  • 1. Nonfatal myocardial infarction is, by itself, an inappropriate end point in clinical trials in cardiology.
    Fleiss JL; Bigger JT; McDermott M; Miller JP; Moon T; Moss AJ; Oakes D; Rolnitzky LM; Therneau TM
    Circulation; 1990 Feb; 81(2):684-5. PubMed ID: 2297869
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction.
    Cannon CP; Sharis PJ; Schweiger MJ; McCabe CH; Diver DJ; Shah PK; Sequeira RF; Greene RM; Perritt RL; Poole WK; Braunwald E
    Am J Cardiol; 1997 Sep; 80(6):696-9. PubMed ID: 9315571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan.
    Dickstein K; Kjekshus J
    Am J Cardiol; 1999 Feb; 83(4):477-81. PubMed ID: 10073846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of acute and long-term beta-adrenergic blockade with alprenolol in definite or suspected myocardial infarction. Background and aims of the study.
    Jürgensen HJ
    Acta Med Scand Suppl; 1984; 680():4-7. PubMed ID: 6375279
    [No Abstract]   [Full Text] [Related]  

  • 5. Design of a placebo-controlled clinical trial of long-acting diltiazem and aspirin versus aspirin alone in patients receiving thrombolysis with a first acute myocardial infarction. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis Post-Thrombolysis (diltiazem) (INTERCEPT) Research Group.
    Boden WE; Scheldewaert R; Walters EG; Whitehead A; Coltart DJ; Santoni JP; Belgrave G; Starkey IR
    Am J Cardiol; 1995 Jun; 75(16):1120-3. PubMed ID: 7762497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FDA's critique of the anturane reinfarction trial.
    Temple R; Pledger GW
    N Engl J Med; 1980 Dec; 303(25):1488-92. PubMed ID: 7432418
    [No Abstract]   [Full Text] [Related]  

  • 7. Multicenter beta-blocker trials: certainties.
    Lubsen J
    Eur Heart J; 1983 Jul; 4 Suppl D():147-9. PubMed ID: 6137375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of acute and long-term beta-adrenergic blockade with alprenolol in definite or suspected myocardial infarction. Study design, patient characteristics and conduct of the study.
    Jürgensen HJ; Andersen MP; Bechsgaard P; Frederiksen J; Hansen DA; Nielsen PB; Pedersen F; Pedersen-Bjergaard O; Rasmussen SL
    Acta Med Scand Suppl; 1984; 680():8-17. PubMed ID: 6375283
    [No Abstract]   [Full Text] [Related]  

  • 9. Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions?
    O'Neil WM; Welner SA; Lip GY
    Thromb Haemost; 2013 Mar; 109(3):497-503. PubMed ID: 23348922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25).
    Antman EM; Morrow DA; McCabe CH; Jiang F; White HD; Fox KA; Sharma D; Chew P; Braunwald E;
    Am Heart J; 2005 Feb; 149(2):217-26. PubMed ID: 15846258
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest.
    Gundersen T; Grøttum P; Pedersen T; Kjekshus JK
    Am J Cardiol; 1986 Jul; 58(1):20-4. PubMed ID: 3524181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.
    O'Donoghue ML; Braunwald E; White HD; Serruys P; Steg PG; Hochman J; Maggioni AP; Bode C; Weaver D; Johnson JL; Cicconetti G; Lukas MA; Tarka E; Cannon CP
    Am Heart J; 2011 Oct; 162(4):613-619.e1. PubMed ID: 21982651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study.
    Montalescot G; Lassen JF; Hamm CW; Lapostolle F; Silvain J; ten Berg JM; Cantor WJ; Goodman SG; Licour M; Tsatsaris A; van't Hof AW
    Am Heart J; 2013 Apr; 165(4):515-22. PubMed ID: 23537967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
    Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
    Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled trial of sotalol for 1 year after myocardial infarction.
    Julian DG; Jackson FS; Szekely P; Prescott RJ
    Circulation; 1983 Jun; 67(6 Pt 2):I61-2. PubMed ID: 6342842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin and recurrent myocardial infarction.
    Krol WF
    JAMA; 1981 Feb; 245(6):572. PubMed ID: 7005479
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical trials of platelet-active drugs in coronary heart disease: summary of design features.
    Furberg CD; May GS
    Circulation; 1980 Dec; 62(6 Pt 2):V49-52. PubMed ID: 7002352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
    James WP; Caterson ID; Coutinho W; Finer N; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Shepherd GM; Rode RA; Renz CL;
    N Engl J Med; 2010 Sep; 363(10):905-17. PubMed ID: 20818901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Double-blind study of betaxolol in patients with acute myocardial infarction].
    Yang XS
    Zhonghua Nei Ke Za Zhi; 1985 Dec; 24(12):712-4, 767. PubMed ID: 2869922
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Armstrong PW; Adams PX; Al-Khalidi HR; Hamm C; Holmes D; O'Neill W; Todaro TG; Vahanian A; Van de Werf F; Granger CB;
    Am Heart J; 2005 Mar; 149(3):402-7. PubMed ID: 15864228
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.